Kornimate/medical-research-clean huggingface dataset:
crossfit's injuries study in grand nancy clubs during 2018-2019

Conditions: CrossFit Injuries

Summary: crossfit is a recent sport that has been democratized since the beginning of the 2000's in france. the 3 major studies of crossfit injuries were conducted in the united states in 2014, brazil in 2016 and the united states in 2017. they show a discrepancy in terms of injuries average, from 19.4% to 31% in relation to an upsurge in the number of crossfit practitioners, the specific training or not of the coaches framing this activity, the practice or not in competition. the main locations of these wounds are highlighted at the shoulders, lumbar region and knees. in france, to date, no epidemiological studies have been conducted on this subject. hypothesis: high incidence of injuries related to a lack of framing, or bad practice and ignorance of crossfit practitioners. objectives : estimate the injuries incident due to the crossfit practice over a 8-month period in an adult population who practice in clubs . research, among the anthropometric, sociodemographic, environmental, and the nature and frequency of practice and training sessions, those which are associated with the occurrence of injury in this cohort.


Eligibility criteria:
inclusion criteria: men and women * 18 years and over * practicing crossfit in a club of the grand nancy * information and non-opposition to research exclusion criteria: * opposition to study

Keywords: crossfit injuries
gabapentin as adjuvant for postoperative pain in pediatric orthopedic surgery

Conditions: Pain, Postoperative; Orthopedic Disorder

Summary: this study is a clinical trial, prospective, randomized and double-blinded. gabapentin oral 10 mg/kg was administered to reduce the pain intensity as well as the opioid consumption in children from 3 months to 16 years submitted unilateral limb surgery.

this study is a clinical trial, prospective, randomized and double-blinded. gabapentin oral 10 mg/kg was administered to reduce the pain intensity as well as the opioid consumption in children from 3 months to 16 years submitted unilateral limb surgery. the children were divided into 2 groups: the gabapentin group (gg) was administered gabapentin 1 to 2 hours before procedure (n-40) and the placebo group (gp) was administered placebo 1 to 2 hours before surgery (n-44). both groups were subjected to the same general anesthesia protocol, opioid free, and femoral and sciatic block with bupivacaine 0.125%. all patients received dipyrone and rescue analgesic used was morphine into 2/2h. the variables studied were age, gender, weight, type of surgery, hemodynamics, postoperative pain and morphine consumption .

Eligibility criteria:
inclusion criteria: children between 3 months and 16 years who were previously healthy submitted to unilateral lower limb surgery exclusion criteria: children cardiac, pulmonary, renal and neurological diseases and allergy and refusal of parents, caregivers and patients to participate in the study.

Keywords: gabapentin postoperative pain child
ultrasound-guided pnb and dpnb for pediatric distal hypospadias surgery

Conditions: Regional Anesthesia; Hypospadias

Summary: hypospadias repair is a urological surgical operation that is very painful in the postoperative period and requires long-term analgesia. a dorsal penial nerve block (dpnb) and pudendal nerve block (pnb), which are regional anesthesia techniques for this operation, are used to provide postoperative analgesia.

the regional anesthesia techniques used for postoperative analgesia in hypospadias repair include the peripheral nerve blocks of pudendal nerve block (pnb) and dorsal penile nerve block (dpnb). ultrasound (us) has recently become increasingly popular in regional anesthesia practice and is used to aid these two peripheral nerve block applications in various pediatric urological procedures. us-guided dpnb has been shown to provide effective and long-term analgesia when compared to caudal epidural block in a recent study on hypospadias surgery in the pediatric population.

Eligibility criteria:
inclusion criteria: * male patients aged between 1-7 years * american society of anesthesiologists (asa) i-ii group * distal hypospadias surgery * able to communicate in turkish * willing to participate to the study (parents and children) exclusion criteria: * less than 1 or more than 7 years of age * a neurological deficit, bleeding diathesis, or a history of local anesthetic allergy; an infection or redness in the injection area, congenital low back anomaly, liver disorder, a psychiatric disorder, mental retardation, or communication problems detected during examination * unwilling to to participate to the study ((parents or children)

Keywords: postoperative pain ultrasound dorsal penile nerve block pudendal nerve block hypospadias
safety study of bms-770767 in subjects with hypercholesterolemia

Conditions: Dyslipidemia

Summary: the purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on ldl cholesterol (ldl-c)


Eligibility criteria:
inclusion criteria: * hypercholesterolemia * currently taking a stable daily dose of statin therapy * serum triglyceride level \< 500mg/dl exclusion criteria * history of myocardial infarction, coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accidents within six months prior to entry into the study * congestive heart failure * diabetes mellitus * active liver disease * impaired renal function * hepatitis c, b and hiv this list is not inclusive additional information is provided in the protocol
personalized estimation of doses delivered during image guided radiation therapy tests

Conditions: Lung Neoplasm; Pelvic Neoplasm; Breast Cancer; Cancer, Otorhinolaryngeal; Cancer Pediatric

Summary: in image-guided radiotherapy (igrt), the repeated and increasingly intensive use of on-board positioning imaging, using 2d or 3d mega-volt (mv) or kilo-volt (kv) imaging devices (cone-beam or cbct scanners), is leading the international medical community to question the potential impact of these additional doses delivered to the patient, especially in at-risk populations such as children and young adults. the doses delivered to the patient by positioning imaging are still relatively unknown, due to the lack of experimental means and software available in clinical routine to easily and accurately evaluate these doses. the main objective is to estimate by personalized monte carlo calculation the physical doses delivered to the patient's organs by the onboard imaging systems during their radiotherapy treatment. the obtained imaging doses will be compared according to different irradiation scenarios commonly used in clinical routine as well as according to the treated location.

the study will consist of 2 successive steps: * step 1 : for a set of patients selected in the clinical centers participating in the study, 3d maps of physical doses delivered to organs by positioning imaging will be calculated based on the patient's ct image used by the treatment planning system (dosimetric calculation performed by monte carlo method). * step 2/ all the new dosimetric data, average organ doses and dose volume histogram, will be the subject of a more global analysis, which will be returned to the project's clinical partner centers.

Eligibility criteria:
inclusion criteria: * igrt (image guided radiation therapy) treatments considered: lung, pelvic (prostate), breast, ent and pediatric cancers * treatment modalities: linac + daily kv-cbct (kilo-volt conebeam cbct) and linac + weekly kv-cbct + daily 2-dimensional-kilo-volt (2d-kv) (adult: lung, prostate, breast, ear nose and throat (ent); pediatric: neuro, ent, thorax and abdomen); cyberknife + daily 2d-kv (adult lung); tomotherapy + daily mv-cbct (mega-volt conebeam cbct) (adult prostate, breast, ent; pediatric ent, thorax and abdomen) exclusion criteria: * patient who has undergone a treatment discontinuation or modification (re-planning) of treatment with an impact on the igrt protocol. * patient for which details on the imaging procedures used during treatment or dicom files (dicom ct, dicom rtstruct) are incomplete will not be included

Keywords: image guided radiation therapy dosimetry x-rays
evaluation of reporting of antibody-drug conjugate associated sepsis-related toxicities

Conditions: Sepsis (SMQ); Opportunistic Infections; Agranulocytosis

Summary: although antibody-drug conjugate(adc) has proved effective in treating many cancers, few patients receiving adc may experience rare but life-threatening sepsis-related toxicities such as sepsis and septic shock. today, data about sepsis/septic shock are scarce. the objective was to investigate reports of sepsis/septic shock adverse events related to adc, including gemtuzumab ozogamicin, trastuzumab emtansine, inotuzumab ozogamicin, enfortumab vedotin, trastuzumab deruxtecan, sacituzumab govitecan, brentuximab vedotin, moxetumomab pasudotox, polatuzumab vedotin, belantamab mafodotin, loncastuximab tesirine and tisotumab vedotin using international pharmacovigilance databases such as the fda adverse event reporting system (faers).

here, investigators use international pharmacovigilance databases such as the fda adverse event reporting system (faers) of individual safety case reports, to identify cases of sepsis-related toxicities related to adc.

Eligibility criteria:
inclusion criteria: case reported in the fda adverse event reporting system (faers) or other international pharmacovigilance database of individual safety case reports to 12/31/2022 adverse event reported were included the report with meddra terms: sepsis(smq), agranulocytosis(smq), opportunistic infections (smq). patients treated with adc included: gemtuzumab ozogamicin, trastuzumab emtansine, inotuzumab ozogamicin, enfortumab vedotin, trastuzumab deruxtecan, sacituzumab govitecan, brentuximab vedotin, moxetumomab pasudotox, polatuzumab vedotin, belantamab mafodotin, loncastuximab tesirine and tisotumab vedotin. other cancer patients received common drug therapies such as chemotherapy, targeted therapy or immunotherapy would also be included as a comparator. exclusion criteria: chronology not compatible between adc and adverse event (sepsis-related toxicities)
three-year follow-up of radioiodine therapy for goitre

Conditions: Tratment of Multinodular Goitre

Summary: background: preadministration of recombinant human thyrotropin (rhtsh) increases the amount and homogeneity of thyroid radioiodine uptake, and when used as an adjuvant can augment the efficiency of 131i therapy by allowing multinodular goitre (mng) volume reduction. objective: the investigators aimed to assess low-dose rhtsh-aided fixed-activity radioiodine therapy outcome in mng patients. design: this was a long-term (36 months) observational study. methods: the investigators measured 24 h thyroid radioiodine uptake (raiu) of 1.4 µci (0.5 mbq) of 131-iodine at baseline and 24 h after intramuscular injection of 0.1 mg rhtsh in 42 patients (aged 42-80 years) who subsequently received 30 mci 131-iodine 24 h after an identical rhtsh injection. urinary iodine was measured at baseline and at 3 months after following a low iodine diet. tsh, free thyroxine (ft4), t3 (t3) and thyroglobulin (tg) were measured at baseline, 24 h, 48 h, 72 h, 168 h, one month, 3, 6, 9, 12, 18, 24 and 36 months after therapy. thyroid volume was assessed by computer tomography at baseline and every 6 months thereafter.


Eligibility criteria:
inclusion criteria: * patients with multinodular goitre exclusion criteria: * aversion to any form of treatment * previous radioiodine therapy * being unable to complete a prolonged follow-up; and * having serious cardiovascular disorders.

Keywords: multinodular goitre recombinant human tsh
a phase iii study comparing two different anti-hiv drug combinations in hiv-positive patients without previous anti-hiv drug therapy

Conditions: HIV Infections

Summary: the purpose of this study is to see how safe a new protease inhibitor (pi) is and how well it fights hiv infection. a pi is a drug that stops hiv from using healthy cells to make more virus. this study will compare the new pi combination of abt-378 plus ritonavir (rtv) with another pi, nelfinavir (nfv). earlier studies suggest abt-378/rtv will be just as good as and perhaps better than nfv at fighting hiv infection.

based on the accumulated studies to date, it is expected that abt-378/ritonavir will provide efficacy that is at least as good as (or superior to) nelfinavir when used in combination with reverse transcriptase inhibitors. patients are equally randomized to one of two treatment arms. in one arm, approximately 330 patients receive abt-378/ritonavir plus nelfinavir placebo. in the other arm, approximately 330 patients receive nelfinavir plus abt-378/ritonavir placebo. in both arms, these protease inhibitors are blinded to the investigator, patient, and sponsor. both arms receive open-label stavudine and lamivudine. vital sign measurements, physical examinations, ecgs, routine clinical laboratory evaluations, and determinations of antiviral and immunologic activity are performed at intervals throughout the study.

Eligibility criteria:
inclusion criteria you may be eligible for this trial if you: * are hiv positive. * have a viral load (level of hiv in your blood) of more than 400 copies/ml. * are age 12 or older. * agree to practice abstinence or use effective methods of birth control during the study. exclusion criteria you will not be eligible for this trial if you: * have taken anti-hiv drugs for more than 14 days in the past, or if you have ever taken d4t or 3tc. * are seriously ill or have an aids-related infection. * are pregnant or breast-feeding. * are taking certain medications.

Keywords: drug therapy, combination administration, oral stavudine hiv protease inhibitors lamivudine reverse transcriptase inhibitors anti-hiv agents nelfinavir abt 378
phase iit trial of sna014

Conditions: Adenocarcinoma of the Stomach; Adenocarcinoma of GE Junction; Pancreatic Cancer Stage

Summary: 68ga labeled claudin 18.2 contrast agent combined with pet/ct for gastric or gastroesophageal junction


Eligibility criteria:
inclusion criteria: * age range of 18 to 75 years old (including boundary values); * individuals with behavioral capacity who voluntarily participate in this clinical study and sign an informed consent form (icf); * diagnosed g/gej adenocarcinoma and pancreatic cancer; * gastroscopy/ct/mri/pet-ct examination results within the past month (if any); * pathological test results and claudin18.2 immunohistochemistry results within the past year (if available). exclusion criteria: * merge patients with other clearly diagnosed malignant tumors: * uncontrolled severe infections or individuals with other serious illnesses; * those with an expected survival period of less than or equal to three months; * pregnant or lactating patients, as well as reproductive age patients who refuse to take appropriate contraceptive measures during this trial; * investigators determine that patients who are not suitable to participate in this study;
trilaciclib combing chemotherapy in the neoadjuvant treatment of osteosarcoma

Conditions: Osteosarcoma

Summary: to evaluate the clinical application value in bone marrow protection of trilaciclib in the neoadjuvant treatment of stage ii/iii classic osteosarcoma in combination with pirarubicin and lobaplatin.

classic osteosarcoma is the most common primary bone malignancy. at present, osteosarcoma is usually treated with preoperative chemotherapy, surgical operation and postoperative chemotherapy. treatment with preoperative chemotherapy is also known as neoadjuvant chemotherapy. neoadjuvant chemotherapy has brought benefits to patients, but safety concerns are inevitable. myelosuppression is a major factor affecting the compliance of patients treated by chemotherapy. patients with chemotherapy-induced myelosuppression(cim) have higher rates of infection, sepsis, bleeding, and fatigue, resulting in hospitalization, hematopoietic growth factor support, blood transfusions (red blood cells and/or platelets) and even death. in addition, cim often leads to dose reduction and delayed administration, which limits the therapeutic dose intensity and therefore affects the anti-tumor efficacy of chemotherapy. currently, there are no approved treatments in osteosarcoma to prevent chemotherapy-induced cell damage. although some treatments may help to address cim when it occurs such as blood transfusions and growth factors, these treatments are pedigree specific, being used after hematopoietic stem progenitor cells damage and could bring additional toxicity. trilaciclib is a highly effective, selective and temporarily reversible inhibitor of cdk4/6. the proliferation of bone marrow hematopoietic stem cells depends on cdk4/6 activity. bone marrow hematopoietic stem cells are blocked in the g1 phase of the cell cycle after exposure to trilaciclib before chemotherapy is given. therefore, this study is conducted to evaluate the clinical application value in bone marrow protection of trilaciclib in the neoadjuvant treatment of stage ii/iii classic osteosarcoma in combination with pirarubicin and lobaplatin.

Eligibility criteria:
inclusion criteria: 1. written informed consent signed; 2. classic osteosarcoma confirmed by histopathology (high grade); 3. newly diagnosed stage ⅱ-ⅲ based on enneking staging criteria; 4. planned to receive neoadjuvant chemotherapy; 5. measurable disease on ct by recist 1.1. 6. no antitumor system therapy received; 7. ecog 0-1 8. adequate organ function. 9. females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication. exclusion criteria: 1. history of malignancies of other type; 2. allergic to study agent; 3. history of psychotropic substance abuse, alcohol or drug use; 4. the researchers considered inappropriate to join the study of any cause.
the effect of modified stepping trainings in frailty elderly with physical performance- a prospective randomized controlled trial

Conditions: Rehabilitation; Training; Respiratory Muscle Strength

Summary: this single-blind, randomized controlled trial compared the effects of modifiled stepping exercise training on flat step and unstable step on the functional outcomes in community-dwelling older adults. the subjects were involved in a step up in 4 directions exercise on each surface, according to their groups, for 50 min/day, 3 days/week, for 6 weeks. the functional outcomes were assessed prior to training, at week 3, week 6 after training and 1 months after training.


Eligibility criteria:
inclusion criteria: * the eligible participants needed ability of independent walking over at least 10 m without any assistive devices, and did not participate in a regular exercise program prior to being involved in the study. older individuals who presented any signs and symptoms that might affect walking and the ability to participate in the study, such as unstable medical conditions, inflammation in the joints of the lower extremities (with a pain scale of more than 5 out of 10 on a visual analog scale), and having sequelae of neurological deficits, were excluded from the study exclusion criteria: * people who were initially recruited, those diagnosed with dementia, depression, severe cardiovascular disease, or mental illness were excluded.

Keywords: balance ability gait training risk of falls community-dwelling older adults
optimal treatment strategy based on for pediatric aml

Conditions: Pediatric Acute Myeloid Leukemia

Summary: the purpose of this study is to optimize therapy according to the known risk factors and treatment response in pediatric acute myeloid leukemia (aml)

i. risk group assessment favorable prognosis group: low risk features + good response intermediate prognosis group: 1. low risk features + delayed response-1 2. standard risk features + good response 3. standard risk features + delayed response-1 poor prognosis group: 1. any high risk features irrespective of treatment response 2. any delayed response-2 irrespective of risk features 3. any refractory state irrespective of risk features 4. any early relapse ii. chemotherapy induction-1: cytarabine + idarubicin induction-2: high dose (hd) cytarabine + mitoxantrone consolidation-1: cytarabine + idarubicin consolidation-2: hd cytarabine + etoposide consolidation-3: hd cytarabine + mitoxantrone consolidation-4: hd cytarabine + etoposide iii. allogeneic hematopoietic stem cell transplantation (hsct) favorable prognosis group: chemotherapy only intermediate prognosis group: chemotherapy or hsct with reduced intensity conditioning poor prognosis group: hsct with myeloablative conditioning

Eligibility criteria:
inclusion criteria: * patients who were newly diagnosed with de novo aml * patients who had recurrent cytogenetic abnormalities of aml even though the bone marrow blast percent is lower than 20% exclusion criteria: * acute promyelocytic leukemia * down syndrome aml * therapy-related aml * aml developed from myelodysplastic syndrome or other marrow failure syndrome * isolated myeloid sarcoma without bone marrow involvement * patients who cannot undergo chemotherapy as scheduled due to serious complications at diagnosis
the efficacy of the kyrobak for chronic low back pain (lbp-2)

Conditions: Low Back Pain

Summary: the purpose of this study is to evaluate the efficacy of the kyrobak continuous passive motion home-use device in relieving low back pain, improving proprioception (balance and fall prevention) and improving the symmetry of muscle function on either side of the spine.

the kyrobak is an electrically operated, continuous passive motion device including a platform that performs angular oscillations. the kyrobak is used at home as an aid to relieve mild-to-moderate low back pain. the study is designed to evaluate the efficacy of daily home use of the kyrobak for 3 weeks and to assess the sustained efficacy 1 week later. the evaluation will include the level of pain using the numerical rating scale (nrs), digital posturography, heart rate variability (hrv), static surface electromyography (semg), a condition-specific low back pain disability status by the oswestry disability index (odi) and subject satisfaction.

Eligibility criteria:
inclusion criteria: * male or female, age 18 or older * level of pain - mild to moderate low back pain (≤5 nrs pain) * chronic - symptoms must have been present for at least 12 weeks or more. * location - lower tip of scapula to back of pelvis * etiology - non-specific exclusion criteria: * patients who have low back pain due to specific and known causes (infection, tumor, osteoporosis, ankylosing spondylitis, fracture, inflammatory process, radicular syndrome (radiating nerve pain from the spine such as sciatica), cauda equinal syndrome (serious neurological disorder where the spinal nerve roots are compressed which can cause). * weight in excess of 265 lbs. (120.4 kg) * pregnant or breastfeeding * recent history of violent trauma * history of previous back surgery * constant progressive, non-mechanical pain (no relief with bed rest) * chronic pain other than low back pain * past medical history of malignant tumor * has taken an investigational drug within the past 30 days prior to entering the study, or currently enrolled in another investigational study * mental disorder that would lead to difficulty in questionnaire completion * any litigation for low back pain * prolonged use of corticosteroids (i.e. used for 3 months or more) * present use of prescription pain medication (i.e. percocet®, oxycodone, vicodin®, etc.) * physical disability that prevents the subject to lie down/get up * drug abuse, immunosuppression, hiv * any other condition which in the physician's opinion would make it unsafe for the subject to be treated.

Keywords: chronic low back pain mild-to-moderate chronic low back pain continuous passive motion devices